anti-misfolded CD38 mAbs (ProMIS Neurosciences/Trellis)

N/A

Report date: 2025/02/01 20:00:06

Base Information

Drug Nameanti-misfolded CD38 mAbs (ProMIS Neurosciences/Trellis)
Drug Alias Nameanticancer monoclonal antibodies misfolded CD38 protein-targeting (Amorfix Life Sciences)
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody
Mechanisms of ActionLymphocyte differentiation antigen CD38 inhibitors
TargetsLymphocyte differentiation antigen CD38
Therapy Area/IndicationsHematologic NeoplasmsNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCanadaUnited States
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesProMIS Neurosciences Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesTrellis Bioscience IncProMIS Neurosciences Inc
Active IndicationsN/A
Inactive IndicationsHematologic NeoplasmsNeoplasms

Other Information

ATC CodeN/A
Related LinksN/A